FCH
LOGC

Freestone Capital Holdings’s LogicBio Therapeutics, Inc. Common Stock LOGC Stock Holding History

Freestone Capital Holdings’s Portfolio LOGC Stock Details LOGC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-600
Closed -$4.58K – 1233
2020
Q4 		$4.58K Hold
600
– – ﹤0.01% 1019
2020
Q3 		$5.45K Buy
+600
New +$4.55K ﹤0.01% 859

Other funds holding LOGC

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

Freestone Capital Holdings's LOGC Position: Q1 2021 in Review

Freestone Capital Holdings sold out of LogicBio Therapeutics, Inc. Common Stock (LOGC) in Q1 2021, closing a stake of 600 shares — an estimated $4.58K sold.

Freestone Capital Holdings first reported a position in LOGC in Q3 2020 and held it in 2 quarters. The position peaked at $5.45K in Q3 2020. 61 funds tracked by Wall St. Rank hold LOGC as of Q1 2021.

  • Freestone Capital Holdings reported no remaining LogicBio Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Freestone Capital Holdings sold 600 LogicBio Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $4.58K.
  • Freestone Capital Holdings first reported a position in LogicBio Therapeutics, Inc. Common Stock in Q3 2020 and held it in 2 quarters.
  • Freestone Capital Holdings's LogicBio Therapeutics, Inc. Common Stock position peaked at $5.45K in Q3 2020.
  • 61 funds tracked by Wall St. Rank held LogicBio Therapeutics, Inc. Common Stock as of Q1 2021.

Based on Freestone Capital Holdings's 13F filing for Q1 2021, filed 17 May 2021.